EGFR and non-small cell lung carcinoma: In conclusion, our findings suggest the efficacy of administering 40 mg osimertinib every other day in patients with EGFR‐mutant NSCLC exhibiting low bodyweight, weight loss, or severe renal impairment, particularly when standard‐dose osimertinib is not well‐tolerated.